NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Palvella Therapeutics, Inc. (PVLA) Stock Analysis

Palvella Therapeutics, Inc. (PVLA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PVLA

$126.58

+$2.66 (+2.15%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PVLA with… →

PVLA Key Statistics

As of Oct 21, 2026
Trading
Open
$125.39
Previous Close
$123.92
Day's Range
122.82–128.48
52-Week Range
68.96–161.38
Volume
245.65K
Valuation
Market Cap
$1.82B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.85
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$41.72M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.41M
1-Year Return
+67.31%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
205.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PVLA closed at $126.58, +67.31% over 1 year.

Palvella Therapeutics, Inc. (PVLA) has a market capitalization of $1.82B.

In fiscal 2025, PVLA reported revenue of $0.00.

PVLA Stock Return by Calendar Year

Palvella Therapeutics, Inc. (PVLA) 10-year return: what $10,000 became

1 year
$10,000 $16,731
+67.31%
5 years
$10,000 $3,588
−64.12%
10 years
$10,000 $9,767
−2.33%

If you had invested $10,000 in Palvella Therapeutics, Inc. (PVLA) 10 years ago, at the close on October 21, 2016, it would have been worth $9,767 at the close on October 21, 2026: −2.33% in total, −0.24% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+20.93%
2025+772.25%
2024−17.58%
2023−82.50%
2022−72.49%
2021+51.20%
2020−30.94%
2019+36.09%
2018−64.77%
2017+437.37%
2016 (partial year)−15.36%

As of October 21, 2026.

PVLA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$41.72M—
2024$0.00−$17.43M—
2023$0.00$18.69M—
2022$0.00−$27.55M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$38.60M−$41.72M—
2024$0.00—−$14.10M−$17.43M—
2023$0.00—−$11.87M$18.69M—
2022$0.00—−$18.04M−$27.55M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Palvella Therapeutics, Inc. (PVLA) at $1.82B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 29.

Over the past 52 weeks the price has ranged from $68.96 to $161.38. The most recent close on file for PVLA is $126.58, dated October 21, 2026. That is +$2.66 (+2.15%) against the previous close. The latest close sits 83.56% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $41.72M. Earnings per share on a trailing basis come to −4.85.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Daily returns over the trailing 10 years annualize to a volatility of 91.68%. Over the trailing twelve months the total return is +67.31%. Across 10 years the annualized return works out at −0.24%.

Growth & Income

The record shows no dividend for PVLA.

The strongest complete calendar year on file is 2025 at +772.25%; the weakest is 2023 at −82.50%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is +20.93%.

Peer Comparison

Palvella Therapeutics, Inc. (PVLA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Palvella Therapeutics, Inc. PVLA $1.82B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Palvella Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Visit website →